describ
mani
centuri
probabl
fi
rst
descript
outbreak
rsv
report
adam
describ
outbreak
nosocomi
chest
infect
infant
neonat
unit
result
death
cytoplasm
inclus
identifi
ed
lung
autopsi
rsv
fi
rst
identifi
ed
coloni
chimpanze
coryza
design
chimpanze
coryz
agent
subsequ
year
later
isol
children
lung
diseas
baltimor
usa
sinc
rsv
recogn
singl
import
viru
caus
acut
respiratori
tract
infect
infant
young
children
throughout
world
although
primarili
respiratori
pathogen
infant
young
children
rsv
infect
reinfect
adult
caus
signifi
cant
diseas
elderli
patient
chronic
lung
diseas
immunocompromis
rsv
classifi
ed
order
mononegaviral
famili
paramyxovirida
greek
para
besid
beyond
myxa
mucu
subfamili
pneumovirina
closelyrel
human
metapneumoviru
famili
member
includ
paramyxivirina
parainfl
uenza
viru
type
mump
morbilliviru
measl
order
mononegaviral
fellow
rna
virus
infl
uenza
infl
uenza
b
resid
famili
orthomyxovirida
greek
ortho
straight
myxa
mucu
rsv
pleomorph
spheric
fi
lament
form
envelop
rna
viru
nm
size
contain
nonseg
singlestrand
negativesens
rna
genom
two
larg
surfac
glycoprotein
fusion
protein
f
attach
protein
g
major
antigen
determin
induc
antibodi
product
two
major
group
rsv
strain
b
distinguish
antigen
characterist
mainli
variat
g
attach
protein
differ
f
fusion
protein
strain
rsv
infect
respiratori
epitheli
cell
attach
cell
surfac
mean
capsular
glycoprotein
g
attach
protein
second
capsular
glycoprotein
f
fusion
protein
mediat
fusion
epitheli
cell
membran
along
adjac
cell
result
format
giant
multinucl
cell
syncytia
viru
name
suggest
anoth
structur
capsularenvelop
protein
sh
small
hydrophob
protein
play
role
syncyti
format
block
cell
deathapoptosi
rsv
virion
assembl
occur
plasma
membran
infect
cell
releas
bud
take
lipid
bilay
membran
deriv
infect
host
cell
infecti
rsv
probabl
fi
lament
form
rsv
paramyxovirus
transmiss
direct
inocul
contagi
secret
hand
selfinocul
eye
nose
transmiss
requir
close
direct
contact
larg
droplet
resid
fomit
like
skin
cloth
clinic
surfac
transmiss
aerosol
featur
infl
uenza
virus
adenoviru
rhinoviru
coronaviru
rsv
incub
period
day
usual
day
viru
replic
nasopharyng
epithelium
spread
lower
respiratori
tract
day
later
respiratori
virus
caus
bronchiol
especi
rsv
direct
cytopath
effect
respiratori
epitheli
cell
characterist
infect
infl
ammatori
process
bronchiol
lead
loss
cilial
motil
submucos
edema
increas
mucu
secret
infi
ltration
leukocyt
necrosi
slough
respiratori
epitheli
cell
small
airway
obstruct
airfl
ow
smalldist
airway
expir
enhanc
dynam
smalldist
airway
narrow
produc
disproportion
turbul
decreas
airfl
ow
caus
airtrap
airtrap
caus
ballvalv
mechan
airway
obstruct
due
intralumin
plug
mucu
cellular
debri
clinic
infl
ammatori
process
smalldist
airway
ie
bronchiol
result
pulmonari
hyperinfl
ation
area
atelectasi
along
wheez
due
smalldist
airway
obstruct
extent
structuralanatom
factor
impact
degre
distal
airway
obstruct
govern
vector
properti
exampl
pouiseil
law
dictat
turbul
airfl
ow
cylind
increas
power
decreas
radiu
physic
sizeabsolut
diamet
distal
airway
inher
variat
infect
individu
infl
ammatori
apoptot
respons
also
infl
uenc
degre
submucos
edema
increas
mucu
secret
slough
epitheli
cell
former
factor
probabl
account
high
incid
respiratori
diseas
younger
smaller
individu
smaller
distal
airway
eg
prematur
infant
latter
individualist
infl
ammatori
respons
continu
fuel
much
research
worldwid
clinic
airtrap
atelectasi
increas
work
breath
due
increas
end
expiratori
lung
volum
decreas
lung
complianc
respiratori
failur
usual
result
worsen
lung
complianc
respiratori
muscl
fatigu
apnea
common
infant
bronchiol
secondari
sever
lung
diseas
central
origin
respiratori
epitheli
cell
usual
recov
within
day
histolog
ciliat
epitheli
cell
take
week
regener
laboratori
human
studi
demonstr
immun
compet
host
clear
viru
follow
natur
rsv
infect
within
week
wherea
immunocompromis
host
defi
cienci
cellular
immun
tend
suffer
sever
diseas
prolong
viral
shed
protect
upper
urti
lower
respiratori
tract
infect
lrti
requir
balanc
humor
cellular
immun
local
secretori
iga
promin
humor
mediat
resist
upper
respiratori
tract
wherea
serum
igg
provid
addit
protect
lower
respiratori
tract
f
g
surfac
glycoprotein
rsv
protein
induc
protect
neutral
antibodi
mainli
subclass
children
neonat
infant
high
level
maternallyderiv
neutral
antibodi
confer
protect
cellular
immun
play
predomin
role
combat
recov
rsv
infect
tlymphocyt
stimul
respons
play
integr
function
antivir
cellmedi
immun
reaction
rsv
infect
primarili
orchestr
rsvinfect
respiratori
epitheli
cell
alveolar
macrophag
helper
cytokin
interferon
interleukin
type
helper
cytokin
antivir
interferon
chemokin
c
cc
cxc
cx
c
subgroup
attract
activ
leukocyt
especi
alveolar
macrophag
rsvinfect
respiratori
tract
cytokin
chemokin
may
enter
system
circul
impact
outli
cell
extrapulmonari
site
fig
much
understand
immun
respons
rsv
infect
come
anim
model
studi
children
sever
diseas
ie
intub
mechan
ventil
children
respiratori
sampl
obtain
therefor
immunopathogenesi
rsv
diseas
great
major
children
develop
mild
respiratori
symptom
may
see
doctor
attend
hospit
larg
infer
misdirect
immun
cascad
characteris
overexuber
releas
infl
ammatori
mediat
cytokin
storm
infi
ltration
rang
monocyt
polymorphonuclear
cell
may
predispos
sever
bronchiol
manipul
host
genet
acquir
factor
contrari
prevail
infl
ammatori
avalanch
theori
studi
chilean
children
mechan
ventil
avail
die
rsv
infl
uenza
bronchiol
north
american
infant
surviv
rsv
infl
uenza
bronchiol
found
blunt
adapt
cellmedi
immun
respons
rel
absenc
cytotox
tcell
fatal
case
especi
rsv
infect
excess
viral
antigen
overwhelm
apoptot
slough
infect
respiratori
epitheli
cell
trial
formalininactiv
vaccin
late
immun
children
suffer
sever
diseas
control
subsequ
contract
natur
rsv
infect
requir
hospit
compar
control
vaccin
children
lack
specifi
c
mucos
antibodi
serum
antibodi
defi
cient
fusioninhibit
neutral
activ
increas
lymphocyt
andor
eosinophil
prolifer
fi
nding
suggest
protect
rsv
infect
necessit
balanc
humor
cellular
immun
howev
rel
contribut
humor
cellular
immun
compon
rsv
infect
immun
subsequ
rsv
infect
still
debat
effect
appropriatelyrestrain
protect
rsv
bronchiol
probabl
requir
viral
neutral
respons
humoralantibodi
cellular
without
excess
rsvspecifi
c
cytotox
tlymphocyt
respons
primari
infect
rsv
lead
acquir
immun
futur
infect
although
natur
acquir
immun
neither
durabl
complet
appear
provid
protect
subsequ
infect
less
sever
despit
extens
studi
major
surfac
glycoprotein
g
fusion
protein
f
even
transcript
antitermin
matrix
protein
reason
lack
acquir
immun
remain
unclear
epidemiolog
rsv
affect
infant
age
year
children
age
year
commonli
respiratori
tract
infect
peak
infect
rate
occur
infant
week
month
age
reinfect
occur
frequent
throughout
life
ill
tend
milder
virtual
children
develop
antibodi
rsv
year
age
rsv
infect
occur
throughout
year
rsv
epidem
occur
predict
annual
interv
winter
month
moder
climat
hot
raini
season
tropic
climat
northern
hemispher
annual
rsv
season
usual
novemb
march
typic
peak
period
decemb
februari
fi
rst
rsv
infect
infant
bronchiolit
pneumon
sign
symptom
requir
hospit
developedresourcerich
nation
usa
rsv
bronchiol
account
hospit
annual
uk
netherland
gener
report
hospit
admiss
rate
children
year
age
usa
europ
around
per
infant
incid
hospit
rate
bronchiol
resourcelimit
area
lack
owe
pauciti
epidemiolog
studi
costsav
restrict
laboratori
confi
rmation
viral
infect
b
strain
circul
concurr
within
rsv
season
distinct
genotyp
within
strain
vari
domin
within
commun
year
year
may
account
frequenc
reinfect
immun
previou
genotyp
evad
approxim
infant
hospit
rsv
infect
bronchiol
develop
respiratori
failur
requir
admiss
picu
amongst
children
resourcerich
countri
admit
picu
bronchiol
report
incid
requir
mechan
noninvas
ventil
vari
depend
countri
region
unit
mortal
rate
hospit
bronchiol
low
increas
children
sever
bronchiol
requir
intens
care
manag
mortal
higher
comorbid
especi
underli
congenit
heart
diseas
chronic
lung
diseas
immunocompromis
neuromuscular
diseas
nosocomi
infect
developingresourcelimit
nation
rsv
common
viral
caus
death
children
year
age
especi
infant
less
year
old
estim
annual
usa
death
caus
rsv
worldwid
death
children
less
year
age
attribut
rsvassoci
lower
respiratori
tract
infect
diagnosi
bronchiol
vast
major
children
around
world
made
clinic
ground
coryza
cough
fever
increas
respiratori
effort
hyperinfl
ation
chest
wheez
fi
ne
crackl
auscult
poor
feed
dehydr
may
back
nonspecifi
c
chest
radiograph
fi
nding
hyperinfl
ation
patchi
atelectasi
andor
normal
oxygen
satur
puls
oximetri
chest
radiographi
differenti
differ
viral
caus
bronchiol
even
viral
bronchiol
bacteri
lrti
addit
clinic
sever
chest
radiographi
chang
correl
well
although
oxygen
satur
measur
may
infl
uenc
clinician
admit
infant
bronchiol
benefi
ts
puls
oximetri
group
proven
author
suggest
certain
clinic
featur
like
cyanosi
crackl
relat
diseas
sever
bronchiol
other
question
valid
reliabl
auscultatori
fi
nding
due
variat
interobserv
agreement
diagnost
method
confi
rming
identifi
viral
pathogen
resourcerich
countri
includ
viral
isol
cultur
direct
immunofl
uoresc
enzymelink
immunosorb
assay
elisa
detect
antigen
reversetranscriptas
polymeras
chain
reaction
rtpcr
detect
nucleic
acid
serolog
test
acut
convalesc
antibodi
viral
titr
usual
clinic
unhelp
seroconvers
may
take
week
poor
respons
rsv
rapid
antigen
detect
test
immunofl
uoresc
enzymelink
immunoassay
gener
overal
sensit
specifi
citi
rang
rtpcr
report
offer
greater
sensit
multiplex
pcr
kit
detect
sever
virus
simultan
readili
avail
commonli
nasopharyng
aspir
test
intub
patient
endotrach
aspir
bronchoalveolar
lavag
util
qualiti
sampl
larg
depend
sampler
techniqu
expertis
govern
accuraci
diagnost
test
rather
site
sampl
bronchiol
common
lower
respiratori
tract
manifest
viral
diseas
typic
result
airtrap
lead
increas
end
expiratori
lung
volum
decreas
lung
complianc
compat
obstruct
lung
diseas
pattern
howev
bronchiol
heterogen
diseas
patient
signific
degre
lung
consolid
restrict
obstruct
lung
diseas
author
discrimin
restrict
obstruct
rsv
lung
diseas
pulmonari
function
test
decreas
respiratori
complianc
ventilatori
indic
oxygen
index
alveolararteri
oxygen
gradient
mean
airway
pressur
addit
fourquadr
alveolar
consolid
chest
radiograph
mechan
ventil
children
everyday
pediatr
practic
clinician
strictli
dichotomis
heterogen
lung
diseas
restrict
obstruct
form
especi
potenti
occur
within
differ
part
lung
usa
european
countri
rsv
bronchiol
rsv
pneumonia
differenti
clinic
presenc
local
crackl
consolid
chest
radiograph
inform
clinician
gener
appreci
pneumon
aspect
sever
bronchiol
whether
label
rsv
bronchiol
rsv
pneumonia
rsv
pneumon
vast
major
children
bronchiol
treat
commun
requir
admiss
hospit
studi
therefor
defi
ne
sever
diseas
need
hospit
approxim
infant
hospit
bronchiol
requir
admiss
picu
pediatr
intensivist
would
regard
picu
admiss
repres
sever
diseas
although
number
clinic
score
system
propos
frequent
util
bronchiol
studi
none
prove
better
clinic
judgement
even
nation
guidelin
indic
hospit
referr
exampl
produc
american
academi
pediatr
scottish
intercollegi
guidelin
network
still
reli
clinic
judgement
interpret
clinic
featur
recognit
risk
factor
predispos
sever
diseas
risk
factor
associ
increas
sever
diseas
divid
host
environment
risk
factor
host
factor
includ
chronolog
age
less
week
prematur
chronic
lung
diseas
congenit
heart
diseas
neurolog
diseas
immunodefi
cienci
addit
indic
suggest
host
genet
predisposit
exampl
surfact
protein
gene
polymorph
sever
rsv
infect
dual
respiratori
infect
rsv
addit
respiratori
virus
concomit
bacteria
also
shown
increas
diseas
sever
indic
need
picu
admiss
mechan
ventil
environment
factor
includ
poverti
overcrowd
malnutrit
exposur
postnat
tobacco
smoke
older
sibl
nurseri
attend
viral
strain
b
appear
import
factor
studi
fail
show
signifi
cant
differ
virul
sever
diseas
b
strain
viral
load
andor
uncontrol
viral
replic
may
well
infl
uenc
diseas
sever
higher
viral
load
tracheal
aspir
ventil
infant
sever
rsv
lrti
compar
mild
diseas
differenti
mean
airway
pressur
oxygen
indic
found
higher
nasal
viral
load
ventil
compar
nonventil
bronchiolit
children
demonstr
initi
studi
howev
subsequ
larger
studi
research
team
fail
fi
nd
signifi
cant
differ
viral
load
andor
uncontrol
viral
replic
factor
support
fi
nding
excess
viral
antigen
overwhelm
apoptot
slough
infect
respiratori
epitheli
cell
fatal
case
chilean
children
die
rsv
especi
infl
uenza
bronchiol
howev
viral
strain
viral
load
alon
fulli
account
variat
diseas
sever
remain
like
variat
preexist
structur
element
distal
respiratori
tree
inher
immun
respons
also
play
key
role
clinic
consequ
peripher
lung
parenchyma
well
describ
rsv
infect
despit
rsv
research
concentr
lung
mechan
pulmonari
immunopatholog
extrapulmonari
effect
beg
question
whether
direct
rsv
effect
ie
rsv
infect
tissu
indirect
secondari
parenchym
lung
diseas
caus
respiratori
compromis
consequenti
prowl
infl
ammatori
mediat
rsv
like
paramyxivirida
infect
nonepitheli
cell
gain
access
receptor
surfac
demonstr
use
monkey
kidney
cell
rsv
cultur
vitro
howev
transit
rsv
distant
organ
would
hematogen
rsvrna
detect
rtpcr
whole
blood
plasma
infant
neonat
alon
mere
indic
cellassoci
rsv
genom
rsvrna
necessarili
viabl
rsv
like
viru
phagocytos
neutrophil
monocyt
escap
white
cell
captor
rsv
would
need
replic
break
yet
demonstr
viabl
rsv
fl
oat
freeli
plasma
would
hold
potenti
distant
rsv
infect
evid
deposit
distant
organ
come
detect
viru
myocardium
liver
cerebrospin
fl
uid
howev
strong
convinc
evid
rsvrelat
infl
ammat
infect
site
less
forthcom
elev
cardiac
troponin
level
infant
sever
rsv
infect
well
describ
unfortun
necessarili
indic
rsvdirect
myocardi
injuri
like
result
right
heart
strain
secondari
sever
lung
parenchym
diseas
likewis
highli
suggest
rais
hepat
transaminas
patient
group
consequenti
hepat
congest
ischemia
due
right
heart
failur
secondari
parenchym
lung
diseas
andor
pulmonari
hypertens
proof
rsv
hepat
would
take
histolog
verifi
cation
ie
liver
biopsi
ethic
reason
ever
go
occur
postmortem
apnea
seizur
undoubtedli
occur
rsv
infect
present
support
rsv
encephalopathi
rsv
enceph
report
frequenc
bronchiolitisinduc
apnea
vari
children
admit
hospit
admit
picu
unfortun
mani
report
fail
adequ
adjust
confound
consequ
hypox
episod
hypercapnea
may
patient
neurolog
statu
relat
hypox
electrolyt
imbal
trigger
rsv
central
infl
uenceeffect
probabl
relat
releas
neurotox
infl
ammatori
chemokin
cytokin
endocrin
impactconsequ
appear
sequela
sever
rsv
pulmonari
diseas
andor
treatment
like
occurr
hyponatremia
hyponatrem
seizur
larg
relat
use
hypotonicelectrolytepoor
intraven
solut
research
requir
scrutin
whether
report
neuroendocrin
stress
respons
rsv
bronchiol
epiphenomenon
refl
ect
sever
rsv
diseas
extrapulmonari
effect
uncommon
like
end
result
releas
infl
ammatori
mediat
direct
effect
oxygen
vital
import
bronchiol
littl
evid
treatment
use
reynold
cook
year
sinc
statement
reynold
cook
clinic
situat
essenti
remain
maintain
adequ
oxygen
hydrat
mainstay
larg
support
treatment
bronchiol
random
control
trial
systemat
review
investig
use
oxygen
lrti
let
alon
bronchiol
evid
use
oxygen
supplement
extrapol
casecontrol
studi
show
hypoxemia
risk
factor
nearfat
asthma
gener
recommend
oxygen
satur
level
maintain
usa
uk
bronchodil
gener
agonist
anticholinerg
ipratropium
bromid
commonli
prescrib
children
bronchiol
north
america
europ
heterogen
studi
design
bronchodil
use
complic
comparison
studi
systemat
review
improv
oxygen
hospit
admiss
rate
durat
hospit
demonstr
studi
investig
benefi
bronchodil
children
bronchiol
requir
mechan
ventil
transient
improv
measur
lung
function
translat
signifi
cant
sustain
clinic
benefi
decreas
length
ventil
routin
use
ventil
patient
nonventil
patient
remain
unsupport
nebul
epinephrin
bronchodil
effect
along
effect
pulmonari
vasoconstrict
reduct
edema
consid
use
use
treatment
bronchiol
although
studi
nebul
epinephrin
bronchiol
show
good
safeti
profi
le
shortterm
improv
clinic
score
compar
placebo
salbutamol
fail
translat
clinic
signifi
cant
improv
oxygen
hospit
admiss
rate
confi
rmed
cochran
review
routin
use
gener
recommend
recent
combin
therapi
dexamethason
shown
promis
decreas
hospit
admiss
rational
use
corticosteroid
inhal
oral
intraven
come
acknowledg
benefi
obstruct
airway
diseas
asthma
abil
inhibit
immun
respons
contribut
pathogenesi
bronchiol
heterogen
studi
design
corticosteroid
administ
make
comparison
studi
diffi
cult
systemat
review
fail
demonstr
benefi
outcom
requir
hospit
admiss
requir
respiratori
support
length
stay
hospit
system
corticosteroid
inhal
corticosteroid
recent
prematurelytermin
intern
multicent
random
control
trial
steroid
treatment
artifi
cialli
ventil
children
rsv
infect
star
trial
investig
potenti
benefi
dexamethason
ventil
children
rsv
bronchiol
fail
demonstr
differ
durat
ventil
supplement
oxygen
length
picu
hospit
stay
dexamethason
placebo
group
mild
sever
oxygen
abnorm
subgroup
likewis
previou
metaanalysi
combin
three
trial
investig
role
corticosteroid
ventil
children
rsv
bronchiol
show
overal
effect
durat
mechan
ventil
hospitalis
data
uncontrol
trial
suggest
may
benefi
use
methylxanthin
theophyllin
caffein
infant
bronchiolitisassoci
apnea
random
doubl
blind
placebo
control
trial
determin
whether
treatment
caffein
citrat
reduc
length
picu
stay
primari
measur
frequenc
apneic
episod
secondari
measur
infant
viral
bronchiol
associ
apnea
progress
qatar
propos
complet
date
april
present
convinc
evid
base
three
trial
fail
demonstr
compel
evid
benefi
chest
physiotherapi
bronchiol
born
systemat
review
hyperton
salin
improv
mucu
viscos
elast
enhanc
mucu
transport
decreas
epitheli
edema
may
counter
bronchiol
pathophysiolog
complic
metaanalysi
four
trial
investig
effect
nebul
hyperton
salin
solut
vs
salin
solut
suggest
nebul
salin
solut
may
hold
benefi
reduc
length
hospit
stay
decreas
clinic
sever
score
howev
none
studi
includ
mechan
ventil
children
ribavirin
purin
nucleosid
analogu
believ
interfer
viral
nucleic
acid
function
ribavirin
activ
rsv
infl
uenza
ribavirin
expens
difficult
deliv
nebul
droplet
adher
ventilatori
circuit
teratogen
therefor
potenti
toxic
patient
treat
team
systemat
review
fail
show
convinc
effect
acut
ventil
set
high
cost
safeti
concern
challeng
deliveri
weak
trial
data
ribavirin
usual
consid
immunocompromis
children
picu
set
europ
american
associ
pediatr
recommend
routin
use
bronchiol
viral
etiolog
report
incid
extrapulmonari
concurr
secondari
bacteri
infect
low
mani
advoc
routin
use
antibiot
bronchiol
howev
critic
care
environ
approach
challeng
bacteri
coinfectionconcomit
bacteri
pneumonia
found
children
requir
mechan
ventil
sever
rsv
bronchiol
comorbid
seem
convey
addit
risk
concomit
bacteri
pneumonia
pediatr
intensivist
consid
tracheobronchi
sampl
intub
picu
admiss
empir
antibiot
cover
antibiot
review
ration
subsequ
microbiolog
result
endogen
surfact
lower
surfac
tension
within
alveoli
alveolarcapillari
membran
level
rational
exogen
surfact
come
fi
nding
low
level
surfact
phospholipid
protein
along
reduc
surfact
function
children
sever
bronchiol
due
endotrach
rout
administr
exogen
surfact
consid
intub
children
systemat
review
three
publish
random
control
trial
patient
highlight
inadequaci
avail
data
variat
surfact
use
studi
design
betweenstudi
length
ventil
control
group
confound
effect
interpret
futur
larg
random
control
trial
hamper
need
multipl
center
obtain
adequ
number
expens
exogen
surfact
pathophysiolog
rational
heliox
densiti
oneseventh
air
would
result
decreas
resist
airfl
ow
number
random
control
even
doubleblind
studi
use
inhal
heliox
perform
infant
bronchiol
none
demonstr
signifi
cant
benefi
cial
effect
real
clinic
term
ie
need
intub
durat
ventil
picu
stay
inhal
nitric
oxid
ino
natur
rout
administr
produc
vasodil
bronchial
tree
therebi
enhanc
blood
fl
ow
ventilationperfus
quotient
singl
studi
examin
effect
inhal
nitric
oxid
respiratori
mechan
ventil
infant
rsv
bronchiol
conclud
ino
appar
bronchodil
effect
major
acut
ill
infant
bronchiol
appear
provid
addit
benefi
use
salbutamol
cochran
review
random
control
trial
ventil
children
adult
analys
effect
ino
acut
hypoxem
respiratori
failur
found
ino
demonstr
statist
signifi
cant
effect
mortal
ventilatorfre
day
transient
improv
oxygen
patient
hypoxem
respiratori
failur
intralumin
mucu
plug
distal
airway
import
pathophysiolog
featur
rsv
bronchiol
dna
releas
degener
leukocyt
present
mucu
plug
contribut
increas
viscos
adhes
cleav
releas
dna
rhdnase
help
liquefi
mucu
anecdot
data
suggest
rhdnase
effect
infant
sever
rsv
bronchiol
multicent
random
doubleblind
placebocontrol
studi
infant
rsv
bronchiol
found
administr
rhdnase
reduc
length
hospit
stay
durat
supplement
oxygen
number
requir
intens
care
mechan
ventil
despit
oxygen
supplement
children
develop
respiratori
failur
artifi
cial
respiratori
support
noninvas
mechan
ventil
may
becom
necessari
applic
continu
posit
airway
pressur
cpap
keep
airway
open
therebi
facilit
expiratori
fl
ow
improv
complianc
reduc
work
breath
enhanc
ga
exchang
support
evid
deliveri
cpap
via
mask
nasal
prong
may
revers
impend
respiratori
failur
avoid
intub
front
humidifi
ed
highfl
ow
nasal
oxygen
demonstr
great
promis
provid
effect
respiratori
support
prevent
progress
respiratori
failur
need
mechan
ventil
shorten
admiss
intub
mechan
ventil
posit
pressur
ventilatori
support
mainstay
support
therapi
children
viral
bronchiolitisinduc
respiratori
failur
due
worsen
lung
complianc
immin
respiratori
collaps
secondari
exhaust
apnoea
respiratori
arrest
alreadi
retrospect
studi
confi
rmed
effect
mechan
ventil
bronchiolitisassoci
respiratori
failur
unfortun
random
control
trial
level
posit
endexpiratori
pressur
peep
ventilatori
strategi
exampl
volumecontrol
versu
pressur
control
high
frequenc
versu
convent
ventil
ventil
children
bronchiolitisinduc
respiratori
failur
perhap
bronchiol
heterogen
lung
diseas
vari
obstruct
restrict
element
rather
homogen
clinic
entiti
maximum
convent
mechan
ventil
high
frequenc
oscillatori
ventil
hfov
fail
stabil
revers
deterior
oxygen
ventil
extracorpor
life
support
ecl
extracorpor
membran
oxygen
ecmo
last
port
call
refractori
case
surviv
rate
eclsecmo
rsv
bronchiol
better
indic
eclsecmo
rang
high
low
report
rate
neurolog
sequela
hyperimmun
rsv
immunoglobulin
rsvig
monoclon
rsv
immunoglobulin
augment
neutral
antibodi
use
immunoprophylaxi
high
risk
patient
shown
reduc
hospit
admiss
rsv
bronchiol
expens
offer
partial
protect
requir
monthli
intraven
rsvig
intramuscular
monoclon
rsv
immunoglobulin
inject
prohibit
expens
lead
mani
costeffect
analys
restrict
use
target
high
risk
group
use
hyperimmun
rsv
polyclon
immunoglobulin
fallen
favour
due
intraven
rout
intraven
volum
requir
increas
risk
advers
outcom
infant
cyanot
heart
diseas
possibl
inactiv
live
vaccin
exampl
measlesmumpsrubella
rsvig
licens
treatment
uk
palivizumab
fi
rst
human
monoclon
antibodi
surfac
f
glycoprotein
rsv
immunoprophylact
agent
gener
favor
studi
extens
palivizumab
shown
reduc
rsvrelat
hospit
admiss
preterm
infant
born
less
week
gestat
infant
born
signifi
cant
congenit
heart
diseas
despit
reduct
hospit
admiss
seriou
rsv
diseas
costbenefi
balanc
infant
born
week
gestat
congenit
heart
diseas
still
debat
intens
although
rsvimpact
trial
examin
effi
caci
palivizumab
preterm
infant
demonstr
overal
reduct
hospit
compar
control
impact
number
requir
picu
admiss
vs
number
requir
mechan
ventil
vs
similarli
despit
overal
reduct
hospit
compar
control
trial
examin
effi
caci
palivizumab
children
congenit
heart
diseas
number
requir
picu
admiss
vs
number
requir
mechan
ventil
vs
signifi
cantli
differ
post
palivizumab
licensur
studi
compar
number
children
requir
picu
admiss
mechan
ventil
rsv
season
prior
palivizumab
rsv
season
follow
prophylact
use
found
signifi
cant
reduct
follow
introduct
palivizumab
current
second
gener
recombin
human
monoclon
antibodi
motavizumab
enhanc
antirsv
neutral
activ
test
intern
guidelin
recommend
rsv
immunoprophylaxi
palivizumab
gener
refl
ect
wide
accept
high
risk
subgroup
children
year
age
chronic
lung
diseas
oxygen
depend
least
day
birth
home
oxygen
prolong
use
oxygen
receiv
medic
therapi
chronic
lung
diseas
children
year
age
usa
infant
less
month
age
uk
hemodynam
signifi
cant
congenit
heart
diseas
cyanot
acyanot
andor
pulmonari
hypertens
children
year
age
sever
congenit
immunodefi
cienci
uk
children
year
age
signifi
cant
congenit
abnorm
airway
neuromuscular
condit
compromis
handl
respiratori
tract
secret
usa
fi
rst
rsv
vaccin
produc
formalininactiv
vaccin
even
though
produc
high
serum
antibodi
level
result
wors
bronchiol
follow
rsv
infect
vaccin
group
control
nonvaccin
children
develop
effect
rsv
vaccin
activ
explor
high
research
prioriti
rsv
vaccin
need
offer
better
protect
natur
infect
effect
fi
rst
week
life
maternallyacquir
antirsv
antibodi
still
present
live
attenu
vaccin
potenti
advantag
deliv
intranas
induc
local
mucos
system
immun
respons
howev
tend
unstabl
virul
revert
back
wildtyp
viru
vaccin
produc
purifi
ed
virus
recombin
vector
plasmid
contain
complementari
dna
viral
genom
gener
target
f
fusion
g
attach
transmembran
glycoprotein
triall
novel
small
molecul
antivir
exampl
small
inhibitori
rna
current
develop
inhibit
rsv
replic
interf
specifi
c
mrna
caus
mrna
degrad
target
downregul
may
hold
potenti
direct
direct
antirsv
therapi
bronchiol
produc
signifi
cant
morbid
mortal
worldwid
everi
year
children
equal
come
bronchiol
underli
chronic
conditionscomorbid
carri
addit
risk
sever
diseas
death
although
basic
support
manag
approach
remain
cornerston
understand
bronchiol
pathogenesi
pathophysiolog
impact
multipl
organ
system
treatment
option
progress
time
